Context Therapeutics Inc. Share Price & Technical Analysis
CNTX · $2.03 (-0.98%)
Healthcare / Biotechnology
$2.03
-0.98%
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the dev…
Price chart
Seasonality
Jun has 2 positive and 2 negative years (last 5 years shown)
-29% return in Jun, 31% avg return in past 3 year Jun month.
69% return in 2026, 69% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 86% | -15% | 18% | -8% | 17% | -29% | – | – | – | – | – | – | 69% |
| 25 | -18% | 0% | -33% | 50% | -33% | 17% | 0% | 14% | 11% | 10% | 0% | 36% | 54% |
| 24 | -9% | 10% | 27% | -13% | 43% | 0% | 10% | 14% | -20% | 10% | -32% | -33% | 6% |
| 23 | 83% | -11% | -25% | 0% | 50% | 78% | -31% | -9% | 36% | -27% | -18% | 22% | 148% |
| 22 | -26% | -5% | 16% | -32% | 47% | -9% | -10% | 0% | -42% | 18% | 8% | -50% | -85% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$240.26M
P/E ratio
—
52W high
$3.62
52W low
$0.54
Volume
5,89,079
Beta
1.57
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Context Therapeutics Inc. share price today?
- Context Therapeutics Inc. (CNTX) last traded around $2.03 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CNTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CNTX. Download the app for real-time alerts.
- How can I analyze Context Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.